Skip to content

Oral Doxycycline for COVID-19 patients

A randomised controlled trial to assess the ability of doxycycline to reduce the need for ICU admission in patients with proven COVID-19 infection (DOXPREVENT.ICU) - DOXPREVENT.ICU

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033867
Enrollment
250
Registered
2021-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B338- Other specified viral diseases Health Condition 2: B342- Coronavirus infection, unspecified Health Condition 3: B342- Coronavirus infection, unspecified

Interventions

Intervention1: Doxycycline: Intention to treat with 200 mg oral doxycycline tablet qd for fourteen days on top of the standard of care (SOC). Control Intervention1: Usual care: Standard care of COVID-

Sponsors

You Breathe We Care
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Able to give informed consent • Male or female, age 40to 90 years • Typical symptoms of COVUD-19 infection: new onset of or exacerbation of cough due to chronic respiratory illness, dyspnea, Increased body temperature (forehead T° >37.6°C; oral T° >38°C; axillary >37.5°C) • SARS-CoV-2 infection demonstrated by PCR • Admission to hospital within 10 days of onset of symptoms

Exclusion criteria

Exclusion criteria: Hypersensitivity to doxycycline; myasthenia gravis; pregnancy; hepatic failure (CHILD-Pugh score C); unable to give informed consent

Design outcomes

Secondary

MeasureTime frame
death, mechanical ventilation, time to discharge, recovery from symptoms, resolution of fever, prolonged hospital stay (7days), supplemental oxygen requiredTimepoint: Day zero to day 14.

Primary

MeasureTime frame
Admission to ICUTimepoint: Day zero to Day 14

Countries

India

Contacts

Public ContactDr Raja Dhar

YOU BREATHE WE CARE

pulmoresearch@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026